Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ch-mAb7f9 · 1 trial · 1 indication
The primary outcome is to determine the safety and tolerability of single, ascending intravenous doses of ch-mAb7F9 in healthy subjects via physical examinations and adverse event, vital sign, electrocardiogram (ECG), and clinical laboratory testing.
| Arm | Type | Description |
|---|---|---|
| Saline | PLACEBO_COMPARATOR | A total of 10 subjects will receive placebo |
| ch-mAb7F9 | EXPERIMENTAL | The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. |
| Name | Type | Description |
|---|---|---|
| normal saline | BIOLOGICAL | saline 225 ml |
| ch-mAb7f9 | BIOLOGICAL | The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml |
Inclusion Criteria: Subjects with the following criteria may be considered for inclusion in the study: 1. Subject voluntarily agrees to participate in this study and signs an IRB-approved informed consent form prior to performing any of the screening procedures. 2. Healthy, determined by the PI ba...
ch-mAb7f9 is an investigational monoclonal antibody being developed for methamphetamine abuse. It is intended to treat this condition, and it is currently in Phase 1 clinical development. The drug is being studied in a completed Phase 1 trial that evaluated its safety in participants with methamphetamine abuse.
ch-mAb7f9 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The company is advancing this monoclonal antibody through clinical development for methamphetamine abuse.
ch-mAb7f9 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for methamphetamine abuse.
ch-mAb7f9 has one completed Phase 1 clinical trial, identified as NCT01603147, titled 'Safety Study of Ch-mAb7F9 for Methamphetamine Abuse.' This trial enrolled 42 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Yes, ch-mAb7f9 is the same drug as Ch-mAb7F9. The name appears in different capitalizations in clinical trial records, but both refer to the same investigational monoclonal antibody being developed for methamphetamine abuse.